Join Growin Stock Community!

Supernus pharmaceuticals, inc.SUPN.US Overview

US StockHealthcare
(No presentation for SUPN)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

SUPN AI Insights

SUPN Overall Performance

SUPN AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

SUPN Recent Performance

-1.10%

Supernus pharmaceuticals, inc.

0.05%

Avg of Sector

-0.31%

S&P500

SUPN PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

SUPN Key Information

SUPN Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

SUPN Profile

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age. The company's commercial products also comprise Qelbree, a selective norepinephrine reuptake inhibitor indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in pediatric patients 6 to 17 years of age; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, its product candidates include Qelbree (SPN-812), which has completed Phase III clinical trials that is used for the treatment of ADHD; SPN-830, a late-stage drug/device combination product candidate for the prevention of off episodes in PD patients; SPN-817, a novel product candidate in Phase I clinical trials for the treatment of severe epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; and SPN-443 and SPN-446, which are in preclinical stage for treating CNS. The company markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. The company was incorporated in 2005 and is headquartered in Rockville, Maryland.

Price of SUPN

SUPN FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

SUPN Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.67
PE Ratio (TTM)
-
Forward PE
20.79
PS Ratio (TTM)
4.36
PB Ratio
3.05
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
89.63%
Net Margin
-5.36%
Revenue Growth (YoY)
8.63%
Profit Growth (YoY)
10.36%
3-Year Revenue Growth
8.13%
3-Year Profit Growth
9.31%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.67
PE Ratio (TTM)
-
Forward PE
20.79
PS Ratio (TTM)
4.36
PB Ratio
3.05
Price-to-FCF
-
Gross Margin
89.63%
Net Margin
-5.36%
Revenue Growth (YoY)
8.63%
Profit Growth (YoY)
10.36%
3-Year Revenue Growth
8.13%
3-Year Profit Growth
9.31%

  • When is SUPN's latest earnings report released?

    The most recent financial report for Supernus pharmaceuticals, inc. (SUPN) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating SUPN's short-term business performance and financial health. For the latest updates on SUPN's earnings releases, visit this page regularly.

  • What is the operating profit of SUPN?

    According to the latest financial report, Supernus pharmaceuticals, inc. (SUPN) reported an Operating Profit of 13.82M with an Operating Margin of 6.53% this period, representing a decline of 36.48% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is SUPN's revenue growth?

    In the latest financial report, Supernus pharmaceuticals, inc. (SUPN) announced revenue of 211.57M, with a Year-Over-Year growth rate of 21.48%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much cash does SUPN have?

    At the end of the period, Supernus pharmaceuticals, inc. (SUPN) held Total Cash and Cash Equivalents of 128.45B, accounting for 0.09 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does SUPN go with three margins increasing?

    In the latest report, Supernus pharmaceuticals, inc. (SUPN) did not achieve the “three margins increasing” benchmark, with a gross margin of 89.13%%, operating margin of 6.53%%, and net margin of -1.94%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess SUPN's profit trajectory and future growth potential.

  • Is SUPN's EPS continuing to grow?

    According to the past four quarterly reports, Supernus pharmaceuticals, inc. (SUPN)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -0.07. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of SUPN?

    Supernus pharmaceuticals, inc. (SUPN)'s Free Cash Flow (FCF) for the period is 45.99M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 215.89% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of SUPN?

    The latest valuation data shows Supernus pharmaceuticals, inc. (SUPN) has a Price-To-Earnings (PE) ratio of -173.57 and a Price/Earnings-To-Growth (PEG) ratio of 1.91. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.